Blood test may cut unnecessary scans for breast cancer patients
NCT ID NCT04968964
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a blood test called DiviTum TKa can help doctors decide to order fewer scans and other tests for women with HR+ HER2- metastatic breast cancer. The trial will enroll 55 women starting a common first-line treatment. Doctors will fill out care plans before and after seeing the blood test results to see if they change their testing plans. The goal is to reduce the burden of frequent testing without missing disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DiviTum® TKa assay (blood test measuring TK1 activity)
What this could lead to
If successful, this could help doctors rely more on a simple blood test and reduce the number of scans and other tests needed to monitor metastatic breast cancer.
What could go wrong
This is a small, early study (55 people) that only looks at whether doctors change their testing plans. It does not directly measure patient outcomes, so the real benefit is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact